Comparative Pharmacology
Head-to-head clinical analysis: HYDROPRES 25 versus NAQUIVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROPRES 25 versus NAQUIVAL.
HYDROPRES 25 vs NAQUIVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine uptake, leading to decreased sympathetic outflow.
NAQUIVAL (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing electrolyte reabsorption and increasing urine output, thereby lowering blood pressure and reducing edema.
1 tablet orally once daily, each tablet contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Dosage may be increased to 2 tablets daily if needed.
Adults: 0.1 mg/kg IV bolus, then 0.1 mg/kg/hour continuous IV infusion, titrated to clinical response. Maximum 0.5 mg/kg/hour.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hr; reserpine: 50-100 hr (terminal, with prolonged adrenergic depletion lasting days)
Terminal elimination half-life: 14-16 hours (healthy adults). Extended to 26-35 hours in heart failure or hepatic cirrhosis due to reduced clearance.
Renal: hydrochlorothiazide 70% unchanged, reserpine ~30% unchanged; fecal: reserpine ~60% metabolites
Renal: 50-60% as unchanged drug; fecal: <10% (biliary); remainder as metabolites (80% renal, 10% fecal).
Category C
Category C
Thiazide Diuretic Combination
Thiazide Diuretic Combination